Stroke

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, Control, Stroke, Blood pressure, Speech, Brain, Pneumonia, Brain ischemia, Kidney, NCCT, Physician, Paralysis, Risk, External carotid artery, Patient, Contrast-induced nephropathy, Cerebrovascular disease, Mortality, Long-term care, Death, Judgement, Deep learning, Nausea, Atherosclerosis, Bleeding, Heart, Neurology, Agent handling, Ministry, Shadow, CTP, Vomiting, Artificial intelligence, Rehabilitation, Dysarthria

The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.

Key Points: 
  • The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.
  • This assist physicians in making decision of acute ischemic stroke management.
  • This system can determine the presence of acute ischemic stroke in approximately 90 seconds.
  • In this way, the facilitated AISIA platform means a lot for ischemic stroke patients and medical experts as well.

Carium and CareDirections Partner to Launch Post-Acute Stroke Care Solution Developed by Atrium Health Wake Forest Baptist

Retrieved on: 
Tuesday, April 2, 2024
Bariatric surgery, Internal medicine, American Heart Association, Health, Neurology, Communication, COMPASS, Incidence, Patient, Stroke, Hospital, Risk, SDOH, Length of stay, Survivor, AHA, Medicare, CMS, Dementia, Nursing

WINSTON-SALEM, N.C., April 2, 2024 /PRNewswire/ -- CareDirections and Carium are announcing the commercial availability of StrokeCP, a clinically and financially validated digital health platform designed by researchers at Atrium Health Wake Forest Baptist and powered by Carium's award-winning patient engagement and virtual care management solution.

Key Points: 
  • The platform pulls together various tools and interventions proven to support care management for stroke survivors post-discharge, leading to improved quality outcomes and reduced cost of care for health systems.
  • "Changes in healthcare delivery and associated costs have challenged providers and patients to monitor and manage care beyond the clinics.
  • It also follows and communicates with patients on behalf of their care providers in the stroke recovery journey and captures patient outcomes and satisfaction with care.
  • This shows the solution can ensure both clinical excellence and financial return, which is crucial for the health systems," said David McCormick, COO at Carium.

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
Saturday, March 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

WOODY ALLEN'S 'COUP DE CHANCE' TO DEBUT APRIL 5 IN U.S. THEATERS NATIONWIDE

Retrieved on: 
Thursday, March 28, 2024
Midnight, Éric Rohmer, The Mad Women's Ball, Venice Film Festival, TheWrap, Stroke, Variety, Mad Women, MPI Media Group, Sensation, Love, Showbiz, Heartbeat, Multimedia, International Emmy Awards, Visitor

NEW YORK, March 28, 2024 /PRNewswire/ -- Woody Allen's newest film is set for release in select theaters across the United States on April 5, 2024. COUP DE CHANCE, a romantic thriller shot entirely in French and starring an acclaimed international cast including Lou de Laâge (International Emmy winner. The Mad Women's Ball), Valérie Lemercier, (The Visitors), Melvil Poupaud, (Eric Rohmer's A Tale of Summer), and Niels Schneider (Heartbeats, How I Killed My Mother) is Allen's 50th film as director. 

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- Woody Allen's newest film is set for release in select theaters across the United States on April 5, 2024.
  • COUP DE CHANCE, a romantic thriller shot entirely in French and starring an acclaimed international cast including Lou de Laâge (International Emmy winner.
  • The Mad Women's Ball), Valérie Lemercier, (The Visitors), Melvil Poupaud, (Eric Rohmer's A Tale of Summer), and Niels Schneider (Heartbeats, How I Killed My Mother) is Allen's 50th film as director.
  • In English, the title means "stroke of luck," and the film centers around the central role of chance and luck in our lives.

$122.5 Million Healthcare Transformation Grant Launches Center for Better Aging

Retrieved on: 
Thursday, March 28, 2024
Community, LDS Family Services, Relaxation, Health equity, Patient, Stroke, City, Health care, Life expectancy, Chronic condition, Patient safety, IDPH, Ageing, Practitioner, Comprehension, Partnership, Risk, Diabetes, Emergency, American College, Social, Longevity, Knowledge, Hospital, University, CBA, HFS, Health, Public health, Chicago State University, Patient safety organization, Heart, Physician, Accreditation, Nursing

CHICAGO, March 28, 2024 /PRNewswire/ -- A one-of-a-kind healthcare collaborative, the Center for Better Aging (CBA) located at St. Bernard Hospital, opens in July with a health equity mandate to serve the growing 50+ population on Chicago's Greater South Side. 

Key Points: 
  • "A whole-person, collaborative approach will be vital to closing the life expectancy gap in the greater South Side community," said Center for Better Aging Executive Director Estrelitta Harmon .
  • CBA partners will elevate the standard of aging adult care and focus on what matters to each patient."
  • St. Bernard Hospital is the lead partner in securing a $122.5 million grant from the Illinois Department of Healthcare and Family Services to fund the nonprofit CBA under the HFS Healthcare Transformation Collaboratives program.
  • HFS is excited to continue this partnership with the Center for Better Aging, as we work together to reduce disparities, better serve customers and ultimately improve health outcomes in South Side communities."

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Akebia, CKD, Patient, Tablet, Public, Stroke, Death, Therapy, Nephrology, Safety, Chronic kidney disease, Dialysis, Anemia, Division, Stanford University, Food, FDA, Pharmaceutical industry

Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.

Key Points: 
  • Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.
  • "As we continue to deliver on our promise for patients and public health, we are eager to closely collaborate with our partners to make this new oral treatment option available to patients."
  • Results from the INNO2VATE program were published in the New England Journal of Medicine: (N Engl J Med 2021; 384:1601-1612); (N Engl J Med 2021; 384:1589-1600).
  • See the Important Safety Information section below, including BOXED WARNING regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access.

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Conference, Organization, Tablet, Caregiver, Anemia, Physician, CKD, Webcast, Patient, Coronary thrombosis, Stroke, AKBA, Death, Renal Support Network, Kidney disease, Nephrology, Kidney, Chronic kidney disease, Dialysis, Division, Safety, Stanford University, Food, Hypoxia, FDA, Erythropoietin, Pharmaceutical industry

CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries.

Key Points: 
  • "At Akebia we are committed to kidney patients, a dedication that has driven our team to achieve this milestone.
  • We believe this commitment uniquely positions the company to execute a successful launch designed to drive toward a potential new oral standard of care for dialysis patients."
  • Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD1, which may be associated with many adverse clinical outcomes.
  • Today, most CKD patients are treated for anemia with injectable erythropoiesis-stimulating agents mostly administered at dialysis centers.

Techint Labs Secures Victory in the 2024 MUSE Creative Awards

Retrieved on: 
Tuesday, March 26, 2024
IAA, Nikon, Saatchi & Saatchi, Organization, Labs, KFC, Kean University, Walt Disney Studios, Tsingtao Brewery, Associate, Silver, Saatchi, Mercedes-Benz, Bank, Stroke, Warner Bros., Lead, CJ, Creativity, Imagination, Kohn Pedersen Fox, Creative, Destination marketing organization, NBCUniversal, Film industry

DENVER, March 26, 2024 /PRNewswire/ -- The MUSE Creative and Design Awards have unveiled their winners for the first competitive season of 2024. Hosted by the International Awards Associate (IAA), these competitions received 8,500 entries from across the globe, affirming their position as prestigious programs honoring creative and design professionals.

Key Points: 
  • DENVER, March 26, 2024 /PRNewswire/ -- The MUSE Creative and Design Awards have unveiled their winners for the first competitive season of 2024.
  • In the first competitive season of 2024, Techint Labs earned Silver in the Corporate Identity Redesign and Brand Identity categories.
  • "It's an honor to be named a winner of two MUSE Awards for our brand projects," said Erin Phipps, Creative Director.
  • As an international award platform, the MUSE Creative and Design Awards attracted entries from internationally renowned organizations.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.